Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure rare eye diseases and developing a vaccine to save lives from COVID-19. The Company’s technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
How do I buy Ocugen stock?
If you want to invest in Ocugen, or any other stock, then choose a reputable stockbroker, sign up, deposit funds from your bank account or credit card, then search for the shares you want to buy. Ocugen shares are listed on the NASDAQ under the ticker “OCGN.” With many brokerage firms offering zero-commission trading and research tools, there are some excellent choices for investors. Robinhood and Webull are the most popular discounted brokers that offer an unique community experience and easy-to-use trading platforms that will satisfy most young investors.
Is Ocugen (OCGN) a good stock to buy?
This year has been a bumpy ride for Ocugen (OCGN) investors, yet rewarding for those who were able to stomach the volatility. Ocugen’s success has been based on its seemingly improbable transformation from a company focused on eye diseases to one chasing the opportunities presented by Covid-19. It partnered with Bharat Biotech, the company developing the Indian version of the coronavirus vaccine called Covaxin. Lately investors have been cheering on the latest development in Ocugen’s attempt to bring the vaccine to market in the US.
Covaxin is a whole-virion inactivated COVID-19 vaccine based on a traditional approach. Unlike most current approved Covid-19 vaccines which use newer messenger RNA technologies or stem cell technologies, Covaxin should address concerns that have led to avoidance of the current vaccines.
Is it a good time to buy Ocugen (OCGN) stock?
According to data from Triangle Finance, the overall consensus is Moderate Buy with a consensus target of $7.90. Longer-term predictions suggested the share price could go up to $8 in one year and exceed $28 by 2027.
However, OCGN stock remains a remarkably risky investment for most investors at this time, especially for potential new investors. There are a lot of “ifs” surrounding Ocugen at this time. Hence, it’s tough to invest in OCGN stock at this time.